Citations

Citations to this article as recorded by  

• Current status and future perspectives of FGF21 analogues in clinical trials
  Zara Siu Wa Chui, Qing Shen, Aimin Xu
  Trends in Endocrinology & Metabolism.2024;[Epub]     CrossRef
• Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis
  Xianlong Ye, Yingli Chen, Jianying Qi, Shenglong Zhu, Yuanyuan Wu, Jingjing Xiong, Fei Hu, Zhimou Guo, Xinmiao Liang
  European Journal of Pharmacology.2023; 952: 175811.     CrossRef
• Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
  Maria Paula Carbonetti, Fernanda Almeida-Oliveira, David Majerowicz
  Archives of Endocrinology and Metabolism.2023;[Epub]     CrossRef
• Exploring the potential mechanism of Simiao Yongan decoction in the treatment of diabetic peripheral vascular disease based on network pharmacology and molecular docking technology
  Fang Cao, Yongkang Zhang, Yuan Zong, Xia Feng, Junlin Deng, Yuzhen Wang, Yemin Cao
  Medicine.2023; 102(52): e36762.     CrossRef
• The Healing Capability of Clove Flower Extract (CFE) in Streptozotocin-Induced (STZ-Induced) Diabetic Rat Wounds Infected with Multidrug Resistant Bacteria
  Rewaa Ali, Tarek Khamis, Gamal Enan, Gamal El-Didamony, Basel Sitohy, Gamal Abdel-Fattah
  Molecules.2022; 27(7): 2270.     CrossRef
• Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
  Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis
  Antioxidants.2022; 11(6): 1060.     CrossRef
• Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
  Jang Won Son
  Endocrinology and Metabolism.2021; 36(1): 57.     CrossRef
• Effects of fasting on skeletal muscles and body fat of adult and old C57BL/6J mice
  Mindaugas Kvedaras, Petras Minderis, Leonardo Cesanelli, Agne Cekanauskaite, Aivaras Ratkevicius
  Experimental Gerontology.2021; 152: 111474.     CrossRef
• The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms
  Mengjie Xiao, Yufeng Tang, Shudong Wang, Jie Wang, Jie Wang, Yuanfang Guo, Jingjing Zhang, Junlian Gu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
  Xinyue Li, Xiaojuan Wu, Yumei Jia, Jing Fu, Lin Zhang, Tao Jiang, Jia Liu, Guang Wang, Claudia Cardoso
  Journal of Diabetes Research.2021; 2021: 1.     CrossRef
• Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
  Brent A. McLean, Chi Kin Wong, Kiran Deep Kaur, Randy J. Seeley, Daniel J. Drucker
  JCI Insight.2021;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Fibroblast growth factor 21 and bone homeostasis
  Yan Tang, Mei Zhang
  Biomedical Journal.2023; 46(4): 100548.     CrossRef
• FGF21 negatively affects long-term female fertility in mice
  Beat Moeckli, Thuy-Vy Pham, Florence Slits, Samuel Latrille, Andrea Peloso, Vaihere Delaune, Graziano Oldani, Stéphanie Lacotte, Christian Toso
  Heliyon.2022; 8(11): e11490.     CrossRef
• Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance
  D. T. W. Lui, C. H. Lee, V. W. K. Chau, C. H. Y. Fong, K. M. Y. Yeung, J. K. Y. Lam, A. C. H. Lee, W. S. Chow, K. C. B. Tan, Y. C. Woo, K. S. L. Lam
  Journal of Endocrinological Investigation.2021; 44(3): 523.     CrossRef
• Skeletal Muscle and Bone – Emerging Targets of Fibroblast Growth Factor-21
  Hui Sun, Matthew Sherrier, Hongshuai Li
  Frontiers in Physiology.2021;[Epub]     CrossRef
• Age‐related bone loss is associated with FGF21 but not IGFBP1 in healthy adults
  Shuen Yee Lee, Kai Deng Fam, Kar Ling Chia, Margaret M. C. Yap, Jorming Goh, Kwee Poo Yeo, Eric P. H. Yap, Sanjay H. Chotirmall, Chin Leong Lim
  Experimental Physiology.2020; 105(4): 622.     CrossRef
• Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21
  Małgorzata Marchelek-Myśliwiec, Violetta Dziedziejko, Monika Nowosiad-Magda, Katarzyna Dołęgowska, Barbara Dołęgowska, Andrzej Pawlik, Krzysztof Safranow, Magda Wiśniewska, Joanna Stępniewska, Maciej Domański, Kazimierz  Ciechanowski
  Kidney and Blood Pressure Research.2019; 44(5): 1207.     CrossRef

Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis. Animal studies have demonstrated a beneficial role of FGF21 in protecting against aberrant lipid profile, while recent development in FGF21 mimetics has provided further insight into the lipid-lowering effects of FGF21 signaling. The present review summarizes the physiological roles of FGF21, and discusses major breakthroughs and limitations of FGF21 mimetic-based therapeutic strategies for treating atherosclerosis.

Citations

Citations to this article as recorded by  

• Higher fasting fibroblast growth factor 21 was associated with a greater decline in postprandial blood pressure
  Jane Yu Ying Ong, Kaveri Pathak, Yun Zhao, Emily Calton, Christopher M. Reid, Mario J. Soares
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(2): 102720.     CrossRef
• Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance
  D. T. W. Lui, C. H. Lee, V. W. K. Chau, C. H. Y. Fong, K. M. Y. Yeung, J. K. Y. Lam, A. C. H. Lee, W. S. Chow, K. C. B. Tan, Y. C. Woo, K. S. L. Lam
  Journal of Endocrinological Investigation.2021; 44(3): 523.     CrossRef
• FGF21 induces autophagy‐mediated cholesterol efflux to inhibit atherogenesis via RACK1 up‐regulation
  Lin Xiaolong, Guo Dongmin, Mihua Liu, Wang Zuo, Hu Huijun, Tan Qiufen, Hu XueMei, Lin Wensheng, Pan Yuping, Lin Jun, Zeng Zhaolin
  Journal of Cellular and Molecular Medicine.2020; 24(9): 4992.     CrossRef
• Two-hundred-liter scale fermentation, purification of recombinant human fibroblast growth factor-21, and its anti-diabetic effects on ob/ob mice
  Qi Hui, Zhen Huang, Shucai Pang, Xuanxin Yang, Jinghang Li, Bingjie Yu, Lu Tang, Xiaokun Li, Xiaojie Wang
  Applied Microbiology and Biotechnology.2019; 103(2): 719.     CrossRef
• Protection Effect of Exogenous Fibroblast Growth Factor 21 on the Kidney Injury in Vascular Calcification Rats
  Yu-Chen Shi, Wei-Wei Lu, Yue-Long Hou, Kun Fu, Feng Gan, Shu-Juan Cheng, Shao-Ping Wang, Yong-Fen Qi, Jing-Hua Liu
  Chinese Medical Journal.2018; 131(5): 532.     CrossRef

Excess energy intake, without a compensatory increase of energy expenditure, leads to obesity. Several molecules are involved in energy homeostasis regulation and new ones are being discovered constantly. Appetite regulating hormones such as ghrelin, peptide tyrosine-tyrosine and amylin or incretins such as the gastric inhibitory polypeptide have been studied extensively while other molecules such as fibroblast growth factor 21, chemerin, irisin, secreted frizzle-related protein-4, total bile acids, and heme oxygenase-1 have been linked to energy homeostasis regulation more recently and the specific role of each one of them has not been fully elucidated. This mini review focuses on the above mentioned molecules and discusses them in relation to their regulation by the macronutrient composition of the diet as well as diet-induced weight loss.

Citations

Citations to this article as recorded by  

• Extracts of Dunkelfelder Grape Seeds and Peel Increase the Metabolic Rate and Reduce Fat Deposition in Mice Maintained on a High-Fat Diet
  Chenlu Yang, Xuelin Tian, Yulei Han, Xueqing Shi, Hua Wang, Hua Li
  Foods.2023; 12(17): 3251.     CrossRef
• Insulin Resistance and Glucose Metabolism during Infection
  Borros Arneth
  Endocrines.2023; 4(4): 685.     CrossRef
• CMKLR1 senses chemerin/resolvin E1 to control adipose thermogenesis and modulate metabolic homeostasis
  Zewei Zhao, Siqi Liu, Bingxiu Qian, Lin Zhou, Jianglin Shi, Junxi Liu, Lin Xu, Zhonghan Yang
  Fundamental Research.2022;[Epub]     CrossRef
• Dissecting biological activities of fibroblast growth factor receptors by the coiled-coil-mediated oligomerization of FGF1
  Natalia Porebska, Marta Pozniak, Mateusz Adam Krzyscik, Agata Knapik, Aleksandra Czyrek, Marika Kucinska, Kamil Jastrzebski, Malgorzata Zakrzewska, Jacek Otlewski, Lukasz Opalinski
  International Journal of Biological Macromolecules.2021; 180: 470.     CrossRef
• Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
  Hwi Seung Kim, Chang Hee Jung
  International Journal of Molecular Sciences.2021; 22(18): 9936.     CrossRef
• Serum interleukin 15 in anorexia nervosa: Comparison to normal weight and obese girls
  Wojciech Roczniak, Agata Mikołajczak-Będkowska, Elżbieta Świętochowska, Zofia Ostrowska, Katarzyna Ziora, Sylwia Balcerowicz, Karolina Górska-Flak, Magdalena Milan, Joanna Oświęcimska
  The World Journal of Biological Psychiatry.2020; 21(3): 203.     CrossRef
• Physiology of energy homeostasis: Models, actors, challenges and the glucoadipostatic loop
  Didier Chapelot, Keyne Charlot
  Metabolism.2019; 92: 11.     CrossRef
• Correlates of zinc finger BED domain-containing protein 3 and ghrelin in metabolic syndrome patients with and without prediabetes
  Rawan AbuZayed, Nailya Bulatova, Violet Kasabri, Maysa Suyagh, Lana Halaseh, Sundus AlAlawi
  Hormone Molecular Biology and Clinical Investigation.2019;[Epub]     CrossRef
• Pharmacotherapy of obesity: Available medications and drugs under investigation
  Eleni Pilitsi, Olivia M. Farr, Stergios A. Polyzos, Nikolaos Perakakis, Eric Nolen-Doerr, Aimilia-Eirini Papathanasiou, Christos S. Mantzoros
  Metabolism.2019; 92: 170.     CrossRef
• Link between chemerin, central obesity, and parameters of the Metabolic Syndrome: findings from a longitudinal study in obese children participating in a lifestyle intervention
  Petra Niklowitz, Juliane Rothermel, Nina Lass, Andre Barth, Thomas Reinehr
  International Journal of Obesity.2018; 42(10): 1743.     CrossRef
• The relationship between the leptin/ghrelin ratio and meals with various macronutrient contents in men with different nutritional status: a randomized crossover study
  Edyta Adamska-Patruno, Lucyna Ostrowska, Joanna Goscik, Barbara Pietraszewska, Adam Kretowski, Maria Gorska
  Nutrition Journal.2018;[Epub]     CrossRef
• The Science of Obesity Management: An Endocrine Society Scientific Statement
  George A Bray, William E Heisel, Ashkan Afshin, Michael D Jensen, William H Dietz, Michael Long, Robert F Kushner, Stephen R Daniels, Thomas A Wadden, Adam G Tsai, Frank B Hu, John M Jakicic, Donna H Ryan, Bruce M Wolfe, Thomas H Inge
  Endocrine Reviews.2018; 39(2): 79.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
• Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial
  Kuat Oshakbayev, Bibazhar Dukenbayeva, Gulnar Togizbayeva, Aigul Durmanova, Meruyert Gazaliyeva, Abdul Sabir, Aliya Issa, Alisher Idrisov
  Nutrition & Metabolism.2017;[Epub]     CrossRef
• Salivary, gingival crevicular fluid and serum levels of ghrelin and chemerin in patients with periodontitis and overweight
  H. F. R. Jentsch, N. Arnold, V. Richter, J. Deschner, T. Kantyka, S. Eick
  Journal of Periodontal Research.2017; 52(6): 1050.     CrossRef

Fibroblast growth factor 21 (FGF21) is an attractive target for treating metabolic disease due to its wide-ranging beneficial effects on glucose and lipid metabolism. Circulating FGF21 levels are increased in insulin-resistant states; however, endogenous FGF21 fails to improve glucose and lipid metabolism in obesity, suggesting that metabolic syndrome is an FGF21-resistant state. Therefore, transcription factors for FGF21 are potential drug targets that could increase FGF21 expression in obesity and reduce FGF21 resistance. Despite many studies on the metabolic effects of FGF21, the transcriptional regulation of FGF21 gene expression remains controversial and is not fully understood. As the FGF21 transcription factor pathway is one of the most promising targets for the treatment of metabolic syndrome, further investigation of FGF21 transcriptional regulation is required.

Citations

Citations to this article as recorded by  

• Glucosamine Enhancement of Learning and Memory Functions by Promoting Fibroblast Growth Factor 21 Production
  Yu-Ming Chao, Hon-Yen Wu, Sin-Huei Yeh, Ding-I Yang, Lu-Shiun Her, Yuh-Lin Wu
  International Journal of Molecular Sciences.2024; 25(8): 4211.     CrossRef
• Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus
  Chang Guo, Li Zhao, Yanyan Li, Xia Deng, Guoyue Yuan
  Journal of Cellular Physiology.2021; 236(1): 55.     CrossRef
• Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome
  Pirkka T. Pekkarinen, Markus B. Skrifvars, Ville Lievonen, Pekka Jakkula, Laura Albrecht, Pekka Loisa, Marjaana Tiainen, Ville Pettilä, Matti Reinikainen, Johanna Hästbacka
  Scientific Reports.2021;[Epub]     CrossRef
• Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects
  Teresa Płatek, Anna Polus, Joanna Góralska, Urszula Raźny, Agnieszka Dziewońska, Agnieszka Micek, Aldona Dembińska-Kieć, Bogdan Solnica, Małgorzata Malczewska-Malec
  Genes.2021; 12(2): 307.     CrossRef
• Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine
  Han Fang, Kirsten P. Stone, Laura A. Forney, Desiree Wanders, Thomas W. Gettys
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• The Presence of Urinary Ketones according to Metabolic Status and Obesity
  Bo-Reum Kim, Jeong Woo Seo, Sang Man Kim, Kyu-Nam Kim, Nam-Seok Joo
  Journal of Korean Medical Science.2020;[Epub]     CrossRef
• MS-275 induces hepatic FGF21 expression via H3K18ac-mediated CREBH signal
  Qi Zhang, Qin Zhu, Ruyuan Deng, Feiye Zhou, Linlin Zhang, Shushu Wang, Kecheng Zhu, Xiao Wang, Libin Zhou, Qing Su
  Journal of Molecular Endocrinology.2019; 62(4): 187.     CrossRef
• Spontaneous ketonuria and risk of incident diabetes: a 12 year prospective study
  Gyuri Kim, Sang-Guk Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Ele Ferrannini, Yong-ho Lee, Nam H. Cho
  Diabetologia.2019; 62(5): 779.     CrossRef
• Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
  Úrsula Martínez-Garza, Daniel Torres-Oteros, Alex Yarritu-Gallego, Pedro F. Marrero, Diego Haro, Joana Relat
  International Journal of Molecular Sciences.2019; 20(19): 4692.     CrossRef
• Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77
  Feiye Zhou, Mengyao Bai, Yuqing Zhang, Qin Zhu, Linlin Zhang, Qi Zhang, Shushu Wang, Kecheng Zhu, Yun Liu, Xiao Wang, Libin Zhou
  Biochemical and Biophysical Research Communications.2018; 495(2): 1936.     CrossRef
• Practical prospects for boosting hepatic production of the “pro-longevity” hormone FGF21
  Mark F. McCarty
  Hormone Molecular Biology and Clinical Investigation.2017;[Epub]     CrossRef
• The regulation of FGF21 gene expression by metabolic factors and nutrients
  Anjeza Erickson, Régis Moreau
  Hormone Molecular Biology and Clinical Investigation.2017;[Epub]     CrossRef
• Diabetes Mellitus and Sepsis
  Silvia C. Trevelin, Daniela Carlos, Matteo Beretta, João S. da Silva, Fernando Q. Cunha
  Shock.2017; 47(3): 276.     CrossRef
• The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus
  Chan-Hee Jung, Sang-Hee Jung, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
  Journal of Diabetes and its Complications.2017; 31(1): 134.     CrossRef
• Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
  Harald Staiger, Michaela Keuper, Lucia Berti, Martin Hrabě de Angelis, Hans-Ulrich Häring
  Endocrine Reviews.2017; 38(5): 468.     CrossRef
• Anti-inflammatory effects of exercise training in adipose tissue do not require FGF21
  Jay W Porter, Joe L Rowles, Justin A Fletcher, Terese M Zidon, Nathan C Winn, Leighton T McCabe, Young-Min Park, James W Perfield, John P Thyfault, R Scott Rector, Jaume Padilla, Victoria J Vieira-Potter
  Journal of Endocrinology.2017; 235(2): 97.     CrossRef
• Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice
  Panos Ziros, Zoi Zagoriti, George Lagoumintzis, Venetsana Kyriazopoulou, Ralitsa P. Iskrenova, Evagelia I. Habeos, Gerasimos P. Sykiotis, Dionysios V. Chartoumpekis, Ioannis G Habeos, Kostas Pantopoulos
  PLOS ONE.2016; 11(9): e0162024.     CrossRef
• Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles
  Ja Young Jeon, Sung-E Choi, Eun Suk Ha, Tae Ho Kim, Jong Gab Jung, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Yup Kang, Kwan-Woo Lee
  Endocrine.2016; 53(1): 97.     CrossRef
• Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury
  Yanlong Liu, Cuiqing Zhao, Jian Xiao, Liming Liu, Min Zhang, Cuiling Wang, Guicheng Wu, Ming-Hua Zheng, Lan-Man Xu, Yong-Ping Chen, Moosa Mohammadi, Shao-Yu Chen, Matthew Cave, Craig McClain, Xiaokun Li, Wenke Feng
  Scientific Reports.2016;[Epub]     CrossRef
• The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis
  Kyung Mook Choi
  Endocrinology and Metabolism.2016; 31(1): 1.     CrossRef
• Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
  Peng Cheng, Fangfang Zhang, Lechu Yu, Xiufei Lin, Luqing He, Xiaokun Li, Xuemian Lu, Xiaoqing Yan, Yi Tan, Chi Zhang
  Journal of Diabetes Research.2016; 2016: 1.     CrossRef
• Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases
  Fangfang Zhang, Lechu Yu, Xiufei Lin, Peng Cheng, Luqing He, Xiaokun Li, Xuemian Lu, Yi Tan, Hong Yang, Lu Cai, Chi Zhang
  Molecular Endocrinology.2015; 29(10): 1400.     CrossRef
• AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells
  Jinmi Lee, Seok-Woo Hong, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
  Molecular and Cellular Endocrinology.2015; 414: 148.     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef